pharmaceutical investing Health Canada Approves SKYRIZI® for Children Living with Moderate to Severe Plaque Psoriasis
pharmaceutical investing AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
pharmaceutical investing AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn's Disease
pharmaceutical investing AbbVie to Present Data at the 2026 European Society for Medical Oncology Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
pharmaceutical investing SKYRIZI® and RINVOQ® Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease at UEGW 2026
pharmaceutical investing AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® in Patients With Moderately to Severely Active Crohn's Disease
pharmaceutical investing New SKYRIZI® and RINVOQ® Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
pharmaceutical investing AbbVie's Telisotuzumab Adizutecan Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
pharmaceutical investing AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
pharmaceutical investing Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
pharmaceutical investing AbbVie Presents Long-Term RINVOQ® Data Showing Continued Repigmentation in Non-Segmental Vitiligo
pharmaceutical investing AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
pharmaceutical investing AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
Independent Review of Syntholene Facility Confirms World Class Proof-of-Performance, Supports Potential for Cost-Competitive Synthetic Aviation Fuel
QIMC Extends Natural Hydrogen and Helium Seismic Program Across the Temiscamingue Graben into Ontario with 26.8 km New Seismic Line
Independent Review of Syntholene Facility Confirms World Class Proof-of-Performance, Supports Potential for Cost-Competitive Synthetic Aviation Fuel
Edgewater Wireless Brings Growing Semiconductor Momentum and Dual-Use Innovation to Canada's Semiconductor Symposium 2026
